EVISA Contact EVISA | Sitemap | Home   
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).

Supporters of EVISA includes:

Frontiers in Pharmacology


PubMed, PubMed Central, Scopus, Web of Science, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Index Copernicus

Source type
First volume
Last volume
Publish city

Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Théophile Godfraind at the Université catholique de Louvain is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.

Pharmacology is a medical science, as was recalled in the anniversary address for the 50th Spring Meeting in Mainz of the German Pharmacological Society in March 2009. This science, of the effect of medicinal bodies, gives us the handle to clarify the fundamental processes of life. It is also the science studying the interactions between chemicals and living beings directed to prevent, ameliorate or cure the deleterious consequences of their diseases, thereby it provides medicine with weapons against diseases. Those major targets offer the opportunity to segment the field not only in studies considering pure basic topics but also by integrating basic and clinical science. This journal's editorial policy aims at identifying the most productive research projects through an evaluation by the scientific community and emphasizing proper use of translational science at both preclinical and clinical levels. Editors  encourage collaboration between clinicians and basic scientists and welcome papers issued from a collaborative strategy between the academic and the private industrial sectors that could benefit to the reversal of the current decline in the production of original medicines.

Imprint     Disclaimer

© 2003 - 2024 by European Virtual Institute for Speciation Analysis ( EVISA )